Buch, Englisch, 264 Seiten, Format (B × H): 125 mm x 190 mm, Gewicht: 313 g
A Citizen's Investigation of the GLP-1 Approval Record, Trial Protocols, and Post-Marketing Safety Signals on Semaglutide and Tirzepatide (Pocketbook Edition)
Buch, Englisch, 264 Seiten, Format (B × H): 125 mm x 190 mm, Gewicht: 313 g
ISBN: 978-3-565-44915-6
Verlag: epubli
THE FILE ON A WEIGHT-LOSS DRUG THAT MARKETED ITSELF FASTER THAN THE FDA COULD REGULATE IT.
In 2017, the FDA approved semaglutide as a diabetes medication. Within four years, it was the most-prescribed weight-loss drug in modern history. Tens of billions of dollars. Off-label scripts. Compounded supply chains. Pediatric approval. The cultural conversation never paused for the regulatory one. This book is the regulatory one.
THE SKINNY SHOT pulls the documentary record on the GLP-1 class. Six years of FDA briefing documents, advisory committee transcripts, trial protocols, post-marketing safety reports, sponsor disclosures, and the price math behind a medication that costs roughly $60 to manufacture and sells for $1,349 a month at the pharmacy counter. Fifteen chapters. 99,000 words.
THE SKINNY SHOT IS INVESTIGATION, NOT ADVICE. It does not recommend treatments. It is the file. Read it, and bring the questions to the physician treating you.
